Method of treating cancers and a pharmaceutical composition that may be used in practicing said method

Abstract

The method of treating a person having a cancer selected from carcinoma, sarcoma or hematopoietic cancer by administering (a) an effective amount of at least one anti-cancer drug selected from the group consisting of an epidermal growth factor receptor (EGFR) inhibitor, a vascular endothelial growth factor receptor (VEGFR) inhibitor and a Raf kinase inhibitor and (b) an effective amount of 5-(4-(6-(4-amino-3,5-dimethyl-phenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy)-benzyl)-thiazolidine-2,4-dione.dihydrochloride provided that said carcinoma is not lung cancer when an EGFR inhibitor is erlotinib. The invention also provides a pharmaceutical composition that may be used in practicing said method.

1 . An anti-cancer pharmaceutical composition for treatment of carcinoma, sarcoma or hematopoietic cancer comprising:
 (a) an effective amount of at least one anti-cancer drug selected from the group consisting of an epidermal growth factor receptor (EGFR) inhibitor,   a vascular endothelial growth factor receptor (VEGFR) inhibitor and   a Raf kinase inhibitor and   (b) an effective amount of   5-(4-(6-(4-amino-3,5-dimethyl-phenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy)-benzyl)-thiazolidine-2,4-dione.dihydrochloride as active ingredients   provided that said carcinoma is not lung cancer when an EGFR inhibitor is erlotinib.   
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein said anti-cancer drug (a) is at least one selected from the group consisting of cetuximab, panitumumab, erlotinib, lapatinib, bevacizumab, SU11248 and vatalanib. 
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein said anti-cancer drug (a) is at least one selected from the group consisting of gefitinib and sorafenib. 
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein said composition is for the treatment of breast cancer, pancreatic cancer, kidney cancer or prostate cancer. 
     
     
         5 . The pharmaceutical composition of  claim 1 , wherein said composition is for the treatment of medulloblastoma, rhabdomyosarcoma, Ewing sarcoma or liposarcoma. 
     
     
         6 . The pharmaceutical composition of  claim 1 , wherein said composition is for the treatment of liposarcoma. 
     
     
         7 . The pharmaceutical composition of  claim 1 , wherein said composition is for the treatment of multiple myeloma or leukemia. 
     
     
         8 . A method of treating a person having a cancer selected from carcinoma, sarcoma or hematopoietic cancer comprising administering:
 (a) an effective amount of at least one anti-cancer drug selected from the group consisting of an epidermal growth factor receptor (EGFR) inhibitor,   a vascular endothelial growth factor receptor (VEGFR) inhibitor and   a Raf kinase inhibitor and   (b) an effective amount of   5-(4-(6-(4-amino-3,5-dimethyl-phenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy)-benzyl)-thiazolidine-2,4-dione.dihydrochloride   provided that said carcinoma is not lung cancer when an EGFR inhibitor is erlotinib.   
     
     
         9 . The method of  claim 8 , wherein said anti-cancer drug (a) is at least one selected from the group consisting of panitumumab, lapatinib, bevacizumab, SU11248 and vatalanib. 
     
     
         10 . The method of  claim 8 , wherein said anti-cancer drug (a) is at least one selected from the group consisting of cetuximab, gefitinib, erlotinib and sorafenib. 
     
     
         11 . The method of  claim 8 , wherein said method is for the treatment of lung cancer, and said anti-cancer drug (a) is gefitinib. 
     
     
         12 . The method of  claim 8 , wherein said method is for the treatment of kidney cancer, and said anti-cancer drug (a) is sorafenib. 
     
     
         13 . The method of  claim 8 , wherein said carcinoma is for the treatment of kidney cancer, and said anti-cancer drug (a) is sorafenib. 
     
     
         14 . The method of  claim 8 , wherein said cancer is medulloblastoma, rhabdomyosarcoma, Ewing sarcoma or liposarcoma. 
     
     
         15 . The method of  claim 8 , wherein said cancer is multiple myeloma or leukemia. 
     
     
         16 . The method of  claim 8 , wherein said cancer is liposarcoma.